Eisai Creates US Subsidiary H3 Biomedicine with up to $200M

Jan 28, 2011

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai has launched US subsidiary H3 Biomedicine with up to $200 million in funding to develop new oncology drugs based on patient genetic information.

Based in Cambridge, Mass., H3 Biomedicine aims to take a personalized medicine approach to developing such drugs by leveraging new insights into the genetic basis of cancer and advances in modern chemistry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Science

In Science this week: gene regulation changes linked to human brain evolution, and more.

Seven Steps

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Arsenic Adaptation

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

NIPT Tests Find Cancer in Some Pregnant Women

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.

Featured White Papers

Reducing the variability of pre-analytical handling of biological samples

Main menu